We just completed a multi-center, randomized, placebo-controlled, double-masked, parallel-group study (NCT03226444) of 'Lacripep™' in Primary Sjogren's Syndrome Dry Eye. Lacripep is a natural constituent of tears that is deficient in dry eye.
Location: United States, Virginia, Charlottesville
Total raised: $3M
Investors 3
Funding Rounds 1
| Date | Series | Amount | Investors |
| 21.11.2024 | Series B | $3M | - |
Mentions in press and media 5
| Date | Title | Description |
| 21.11.2024 | TearSolutions Raises $3M in Series B Funding | TearSolutions, Inc., a Charlotesville, VA-based biotech company developing therapies for the treatment of ocular surface related diseases, closed a $3M Series B funding round. The company intends to use the funds to accelerate its developme... |
| 19.03.2021 | 120Water on growth tear, closes on $4.5M funding round | - |
| 21.03.2019 | Charlottesville Biotech Startup TearSolutions is $6.4M Closer to Defeating Dry Eyes | Charlottesville startup TearSolutions is moving ever closer to commercialization after hauling in a $6.4 million funding round. The company, which launched in 2013 as a spinout of the University of Virginia, is developing a drug called Lacr... |
| 07.02.2018 | Biotech with treatment for chronic dry eye disease tied to diabetes raises seed capital | The $500,000 seed round comes from two funding sources supported by Pennsylvania: Life Sciences Greenhouse of Central Pennsylvania (LSGCP) and a branch of the state economic development arm Ben Franklin Technology Partners/Central and North... |
| - | Biotech with treatment for chronic dry eye disease tied to diabetes raises seed capital | Biotech startup Ocunova, a spin-out from the Penn State University College of Medicine, has closed a fresh round of seed funding to support clinical trials for a treatment aimed at a chronic dry eye condition related to diabetes. The treatm... |